Drugs / glutathione sodium salt
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06296212 | Jun 2024 → Jun 2025 overdue | pneumonia | Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glutathione sodium salt | “TAD® 600 mg/4 mL powder and solvent for solution for injection, 1 vial powder (glutathione sodium salt 646 mg) + 1 solvent ampoule (4 mL water for injection) reconstituted...” NCT06296212 ↗ |
| Route | Intravenous | “administered intravenously” NCT06296212 ↗ |